Serum levels of type I and III procollagen fragments in Paget's disease of bone.
Patients with Paget's disease of bone were found to have elevated serum levels of type I procollagen carboxyterminal peptide (pColl-I-C) which correlated with other measurements of disease activity. The elevated levels of pColl-I-C decreased within hours after the injection of salmon calcitonin and within weeks after oral dichloromethylene diphosphonate treatment. The decrease in serum pColl-I-C after a single injection of salmon calcitonin was associated with a decrease in urinary hydroxyproline excretion, both of which rose toward pretreatment values within 7 h. The pColl-I-C levels remained normal for months after dichloromethylene diphosphonate therapy was discontinued. Using a RIA for the type III procollagen amino-terminal peptide (pColl-III-N), it was found that serum levels were also elevated in patients with Paget's disease. The levels of pColl-III-N also decreased after the injection of salmon calcitonin, but not to the same extent as those of pColl-I-C. After chronic therapy with dichloromethylene diphosphonate, serum levels of pColl-III-N decreased, but not into the normal range. We postulate that whereas pColl-I-C is derived from synthesis of mineralized bone collagen, pColl-III-N is derived from the loose fibrous stroma replacing marrow in areas closely associated with active Pagetic bone disease.
D000918:Antibody Specificity; D002116:Calcitonin / Q000494:pharmacology; D004002:Clodronic Acid / Q000627:therapeutic use; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D010001:Osteitis Deformans / Q000097:blood* / Q000188:drug therapy; D010446:Peptide Fragments / Q000097:blood; D011347:Procollagen / Q000097:blood*; D011863:Radioimmunoassay; D013997:Time Factors
D010446:Peptide Fragments; D011347:Procollagen; D004002:Clodronic Acid; C028815:salmon calcitonin; D002116:Calcitonin; D006909:Hydroxyproline